This website uses cookies to ensure you get the best experience on our website.
Privacy Statement
Privacy Statement
Our mission is to create highly integrated drug-device combination products for affordable-best-quality, featuring nebulization of high value therapeutic drugs that include small molecule synthetics and large molecule biologics, as either solutions, suspensions, and even difficult-to-deliver high viscosity drugs.
In order to achieve optimal aerosol performance for diverse formulations, we closely work with our partners to tailor the components and parameters of our mesh technology.
By combining the strength of Taiwan's world-class manufacturing industry and a well-established GMP certified manufacturing facility, our products have received approval by multiple health authorities and have been launched in selected regions.
We bring significant value to global pharma partners through a cost efficient and risk minimized pathway, designing combination products that can provide great contributions in the respiratory field.
HCmed Innovations Foundation
Completion of Deepro Prototype
ISO 13485 & Deepro CE Mark Approval
Deepro TFDA Approval
HCmed Licensing Agreement in Brazil (Deepro)
Deepro INMETRO and ANVISA Approval
Deepro (inAResp) Launch in Brazil
Pulmogine release in ERS 2019
Pulmogine NMPA Approval
Pulmogine (SMC) Launch in China
Development Agreement for Combination Product
Pulmogine FDA 510(k) Approval
Chief Executive Officer (CEO) and founder of HCmed Innovations Co., Ltd. Jason Cheng has over 10 years of experience in inhalation medical devices. Prior to HCmed, he successfully led a design company specialized in the development of electrical systems for mesh nebulizers. Among his expertise, he is also highly familiar with quality design standards and procedures of medical devices. Jason founded HCmed Innovations as a professional firm in the inhaled drug-device combination field in 2014. Since then, he has led the HCmed team to design, develop, and manufacture highly effective mesh nebulizers, successfully partnering with top global pharmaceutical companies and launching HCmed’s products in selected regions.
Chief Operating Officer (COO) of HCmed Innovations Co., Ltd. Leon Tsai has an extended trajectory of over 15 years in the development and manufacturing of medical devices. He has designed and developed several medical devices such as body fat monitors, sphygmomanometers, skin analyzers, and mesh nebulizers, experience that has provided him with vast knowledge on the design and requirements of medical equipment as well as regulatory affairs. In 2014, Leon Tsai and Jason Cheng founded HCmed Innovations to focus on the respiratory field. Currently, he serves as board director and COO, where he oversees the company’s operation, the development of new innovative devices, and the integrated system of drug-device combination developments.
Board Director of HCmed Innovations Co., Ltd., focused on formulation and drug-device combination products. Dr. Shah is a highly successful pharmaceutical entrepreneur and executive who has been at Vivo Capital since March 2010. He is also the founder and executive chairman of Semnur Pharmaceuticals. Dr. Shah currently serves as chairman of the board of Essentialis Therapeutics, board member of Biotie Therapies (NASDAQ: BITI), and a member of the board of trustees of St. John’s University. At the same time, he is also a board member and charter member of EPPIC and a charter member of TIE.
Board Director of HCmed Innovations Co., Ltd., focused on production automation. Simon Hsieh is a creditable executive with vast experience in the mobile phone, display, and automation industries. He has previously served as VP at Manz AG, as well as direct of strategic planning at of QISDA and AUO. Simon currently focuses on the productions of respiratory medical devices and low-level laser therapeutic medical devices, leading the planning for implementation of automation systems at HCmed Innovations.
Board Director of HCmed Innovations Co., Ltd., focused on investment and management. Jennifer Lin, Investment Manager of H&QAP, has been with H&QAP since 2016 and is responsible for VC investment in Healthcare and Technology sectors. Prior to joining H&QAP, she accumulated over 8 years of audit, tax and financial advisory related experiences with various industry clients in Deloitte. Jennifer Lin is a Certified Public Accountant (CPA) in Taiwan and the USA.
Pravin Soni is a consultant with over 30 years of experience. He has experience with successful FDA interactions relating to CMC aspects of drug, device, and combination medical products development, from early stage development through commercial launch. He was Vice President of Development at Alexza Pharmaceuticals where he led the development of the novel Staccato inhalation drug delivery platform. He served as a senior VP and CTO at Elevation Pharmaceuticals, where he was responsible for the development of a combination product using nebulized glycopyrrolate for the inhalation treatment of COPD that was successfully acquired by Sunovion pharmaceuticals for $430 million in 2012. He was co-founder of Patara Pharma where he was responsible for Development, Manufacturing, Quality and IP. Patara was acquired by Roivant Sciences and spun-off as Respivant Sciences, a Roivant Division. As Exec. VP of Respivant Sciences he was responsible for IP, Quality Assurance, Development, CMC-regulatory, Manufacturing and scale-up of a drug-device combination product for the treatment of refractory cough in Idiopathic Pulmonary Fibrosis (IPF). As current President of PharmaCRO, he provides consulting services that integrate product design, manufacturing, regulatory, quality, clinical, toxicology, and marketing requirements to identify the most efficient route to commercialization of safe, efficacious and reliable drug, device and combination medical products. Pravin has a Ph.D. in Polymer Science and Engineering from Case Western Reserve University. He has been granted sixty-three (63) patents.
Vera Wu is a Partner in KyrMar Advisory Services focused on providing local and multinational biotech and pharmaceutical companies support in their go-to-market and market expansion strategies and business development support in Taiwan. Vera led the business development efforts for EirGenix’s global trastuzumab licensing and supply deal with Sandoz Pharmaceuticals. Ms. Wu relocated from New York City where she last worked as a senior leader at Pfizer for over ten years. While there, Ms. Wu held various commercial roles including US LOE Asset Lead with responsibility for $3.0B USD in sales. Ms. Wu was a founding member of Pfizer’s Biosimiliar team responsible for gaining approval and launching ELELYSO globally. As a member of the Pfizer Corporate Strategy and Innovation team, Ms. Wu advised Pfizer’s CEO and executive leadership team on strategic options for complex corporate level opportunities. Before joining Pfizer, Ms. Wu worked as a principal consultant in Business Consulting Services for IBM (formerly PriceWaterhouseCoopers). Ms. Wu received her Master of Business Administration (MBA) in Finance and Strategic Management at The Wharton School, University of Pennsylvania in Philadelphia, Pennsylvania, and a Bachelor of Electrical Engineering from the University of Delaware.
F. Scott Fleming is an accomplished pharmaceutical, drug delivery, and digital health executive with 28 years of experience developing, bringing to market, and monetizing new therapeutics. He has vast experience in the inhalation therapy industry and co-founded specialty pharmaceutical and drug delivery systems company MicroDose Therapeutx, which developed leading edge digital inhalers and respiratory diseases therapies. At MicroDose he negotiated numerous license agreements and joint ventures with major pharma and biotech partners, and in July 2013 sold the company to Teva Pharmaceuticals under a deal worth $165 million. He thereafter joined Teva’s Global Commercial Respiratory group and was global brand director for eConnectivity in Teva’s respiratory franchise for over 3 years. His career encompasses business development and strategy, contract negotiations, sales & marketing, brand development, fundraising, and multiple Director’s positions. He is an inventor on over one dozen patents and has been published in multiple peer reviewed journals. He resides in Amsterdam, the Netherlands.
HCmed’s headquarters is located in Taipei City. Currently, our company counts with a GMP certified manufacturing site in Zhonghe, New Taipei City, while a second site is under construction in Wuxi, China.
Companies and institutions based in the US, Japan, China, and Taiwan are among our main local and foreign investors. HCmed Innovations is constantly expanding its parnerships worldwide, aiming to deliver top-quality inhalation treatment to people around the world.
1:Wuxi, China: GMP Manufacturing Site
2-1:Taipei City: Headquarters and R&D Center
2-2:New Taipei City: GMP Manufacturing Site
1:VIVO Capital
2:DCI Partners
3:H&Q Asia Pacific
4:Cathay Life Insurance | Mega Bank
1:Abbott, Brazil
2:China AstraZeneca, I-Campus Partner
3:SinoMedCare Biotech, China
